Stem Cell Theory of Cancer: Implications for Drug Resistance and Chemosensitivity in Cancer Care
- PMID: 35326699
- PMCID: PMC8946169
- DOI: 10.3390/cancers14061548
Stem Cell Theory of Cancer: Implications for Drug Resistance and Chemosensitivity in Cancer Care
Abstract
When it concerns cancer care and cancer therapy, drug resistance is more than an obstacle to successful treatment; it is a major cause of frustration in our attempts to optimize drug development versus therapy development. Importantly, overcoming the challenges of drug resistance may provide invaluable clues about the origin and nature of cancer. From this perspective, we discuss how chemoresistance and chemosensitivity in cancer therapy could be directly linked to the stem cell origin of cancer. A stem cell theory of cancer stipulates that both normal stem cells and cancer stem cells are similarly endowed with robust efflux pumps, potent antiapoptotic mechanisms, redundant DNA repair systems, and abundant antioxidation reserves. Cancer stem cells, like their normal stem cell counterparts, are equipped with the same drug resistance phenotypes (e.g., ABC transporters, anti-apoptotic pathways, and DNA repair mechanisms). Drug resistance, like other cancer hallmarks (e.g., tumor heterogeneity and cancer dormancy), could be intrinsically ingrained and innately embedded within malignancy. We elaborate that cellular context and the microenvironment may attenuate the effects of cancer treatments. We examine the role of circadian rhythms and the value of chronotherapy to maximize efficacy and minimize toxicity. We propose that a stem cell theory of drug resistance and drug sensitivity will ultimately empower us to enhance drug development and enable us to improve therapy development in patient care.
Keywords: cancer stem cells; chemosensitivity; chronotherapy; circadian rhythm; clonal origin; drug development; drug resistance; therapy development; unified theory.
Conflict of interest statement
The authors declare no conflict of interest. The funders had no role in the writing of the manuscript or in the decision to publish the results.
Figures
Similar articles
-
Stem Cell Theory of Cancer: Rude Awakening or Bad Dream from Cancer Dormancy?Cancers (Basel). 2022 Jan 27;14(3):655. doi: 10.3390/cancers14030655. Cancers (Basel). 2022. PMID: 35158923 Free PMC article.
-
Curing Cancer: Lessons from a Prototype.Cancers (Basel). 2021 Feb 7;13(4):660. doi: 10.3390/cancers13040660. Cancers (Basel). 2021. PMID: 33562202 Free PMC article.
-
Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care.Cancers (Basel). 2024 Mar 14;16(6):1151. doi: 10.3390/cancers16061151. Cancers (Basel). 2024. PMID: 38539487 Free PMC article.
-
Insights into new mechanisms and models of cancer stem cell multidrug resistance.Semin Cancer Biol. 2020 Feb;60:166-180. doi: 10.1016/j.semcancer.2019.07.022. Epub 2019 Jul 29. Semin Cancer Biol. 2020. PMID: 31369817 Review.
-
Chrono-Drug Discovery and Development Based on Circadian Rhythm of Molecular, Cellular and Organ Level.Biol Pharm Bull. 2021;44(6):747-761. doi: 10.1248/bpb.b21-00277. Biol Pharm Bull. 2021. PMID: 34078807 Review.
Cited by
-
Discovery of new symmetrical and asymmetrical nitrile-containing 1,4-dihydropyridine derivatives as dual kinases and P-glycoprotein inhibitors: synthesis, in vitro assays, and in silico studies.J Enzyme Inhib Med Chem. 2022 Dec;37(1):2489-2511. doi: 10.1080/14756366.2022.2120478. J Enzyme Inhib Med Chem. 2022. PMID: 36093880 Free PMC article.
-
A Triphenylphosphonium-Functionalized Delivery System for an ATM Kinase Inhibitor That Ameliorates Doxorubicin Resistance in Breast Carcinoma Mammospheres.Cancers (Basel). 2023 Feb 25;15(5):1474. doi: 10.3390/cancers15051474. Cancers (Basel). 2023. PMID: 36900267 Free PMC article.
-
Stem Cell Origin of Cancer: Implications of Oncogenesis Recapitulating Embryogenesis in Cancer Care.Cancers (Basel). 2023 Apr 27;15(9):2516. doi: 10.3390/cancers15092516. Cancers (Basel). 2023. PMID: 37173982 Free PMC article.
-
Omission of Axillary Surgery After Neoadjuvant Therapy in Her2-Positive Breast Cancer: Who Are the Candidates?Cancers (Basel). 2025 Feb 7;17(4):562. doi: 10.3390/cancers17040562. Cancers (Basel). 2025. PMID: 40002157 Free PMC article.
-
Multidrug Resistance: Are We Still Afraid of the Big Bad Wolf.Pharmaceuticals (Basel). 2025 Jun 14;18(6):895. doi: 10.3390/ph18060895. Pharmaceuticals (Basel). 2025. PMID: 40573290 Free PMC article. Review.
References
-
- Koch R. Die Atiologic der Tuberkulose. Berl. Klin. Wochenschr. 1882;15:221–230.
Grants and funding
LinkOut - more resources
Full Text Sources